The closing price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was $1.48 for the day, down -6.92% from the previous closing price of $1.59. In other words, the price has decreased by -$0.1100 from its previous closing price. On the day, 1119803 shares were traded. ADAP stock price reached its highest trading level at $1.6360 during the session, while it also had its lowest trading level at $1.4200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of ADAP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.92 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bryan Garnier on March 24, 2023, initiated with a Buy rating and assigned the stock a target price of $3.60.
On January 03, 2023, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
Mizuho Upgraded its Neutral to Buy on November 09, 2022, while the target price for the stock was maintained at $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 17 when Rawcliffe Adrian sold 30,080 shares for $0.67 per share. The transaction valued at 20,244 led to the insider holds 44,848 shares of the business.
Bertrand William C JR sold 18,908 shares of ADAP for $12,725 on Jan 17. The Chief Operating Officer now owns 7,785 shares after completing the transaction at $0.67 per share. On Jan 17, another insider, Norry Elliot, who serves as the Chief Medical Officer of the company, sold 18,276 shares for $0.67 each. As a result, the insider received 12,300 and left with 7,785 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 361.12M and an Enterprise Value of 225.00M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.69 while its Price-to-Book (P/B) ratio in mrq is 3.81. Its current Enterprise Value per Revenue stands at 3.17 whereas that against EBITDA is -2.15.
Stock Price History:
Over the past 52 weeks, ADAP has reached a high of $1.79, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is 0.9897, while the 200-Day Moving Average is calculated to be 0.8380.
Shares Statistics:
ADAP traded an average of 1.52M shares per day over the past three months and 1.56M shares per day over the past ten days. A total of 164.52M shares are outstanding, with a floating share count of 156.36M. Insiders hold about 31.10% of the company’s shares, while institutions hold 58.73% stake in the company. Shares short for ADAP as of Feb 15, 2024 were 2.93M with a Short Ratio of 1.92, compared to 5.77M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.29% and a Short% of Float of 2.72%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of $0 and a low estimate of -$0.17, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.33 and -$0.52 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.49, with 4 analysts recommending between -$0.4 and -$0.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $39M to a low estimate of $2M. As of the current estimate, Adaptimmune Therapeutics Plc ADR’s year-ago sales were $11.03M, an estimated increase of 85.60% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $9.4M, a decrease of -80.30% less than the figure of $85.60% in the same quarter last year. There is a high estimate of $20M for the next quarter, whereas the lowest estimate is $5M.
A total of 6 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $99.1M, while the lowest revenue estimate was $62M, resulting in an average revenue estimate of $80.54M. In the same quarter a year ago, actual revenue was $27.15M, up 196.70% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $44.11M in the next fiscal year. The high estimate is $75M and the low estimate is $22.8M. The average revenue growth estimate for next year is down -45.20% from the average revenue estimate for this year.
